;PMID: 10700176
;source_file_1359.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..32] = [t:0..32]
;1)sentence:[e:37..159] = [t:37..159]
;2)section:[e:163..330] = [t:163..330]
;3)section:[e:334..458] = [t:334..458]
;4)sentence:[e:462..535] = [t:462..535]
;5)sentence:[e:536..736] = [t:536..736]
;6)sentence:[e:737..918] = [t:737..918]
;7)sentence:[e:919..1130] = [t:919..1130]
;8)sentence:[e:1131..1300] = [t:1131..1300]
;9)sentence:[e:1301..1434] = [t:1301..1434]
;10)sentence:[e:1435..1774] = [t:1435..1774]
;11)section:[e:1778..1823] = [t:1778..1823]

;section 0 Span:0..32
;Nat Genet  2000 Mar;24(3):245-50
(SEC
  (FRAG (VBG:[0..3] Nat) (IN:[4..9] Genet) (CD:[11..15] 2000)
        (CD:[16..23] Mar;24-LRB-) (CD:[23..24] 3) (-RRB-:[24..25] -RRB-)
        (CD:[25..29] :245) (HYPH:[29..30] -) (CD:[30..32] 50)))

;sentence 1 Span:37..159
;AXIN1 mutations in hepatocellular carcinomas, and growth suppression in
;cancer  cells by virus-mediated transfer of AXIN1.
;[37..42]:gene-rna:"AXIN1"
;[56..81]:malignancy:"hepatocellular carcinomas"
;[153..158]:gene-rna:"AXIN1"
(SENT
  (NP-HLN
    (NP
      (NP
        (NP (NN:[37..42] AXIN1) (NNS:[43..52] mutations))
        (PP (IN:[53..55] in)
          (NP (JJ:[56..70] hepatocellular) (NNS:[71..81] carcinomas))))
      (,:[81..82] ,) (CC:[83..86] and)
      (NP
        (NP (NN:[87..93] growth) (NN:[94..105] suppression))
        (PP (IN:[106..108] in)
          (NP (NN:[109..115] cancer) (NNS:[117..122] cells)))))
    (PP (IN:[123..125] by)
      (NP
        (NP
          (ADJP (NN:[126..131] virus) (HYPH:[131..132] -)
                (VBN:[132..140] mediated))
          (NN:[141..149] transfer))
        (PP (IN:[150..152] of)
          (NP (NN:[153..158] AXIN1)))))
    (.:[158..159] .)))

;section 2 Span:163..330
;Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T,
;Ishiguro  H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T,
;Yamaoka Y,  Nakamura Y.
(SEC
  (FRAG (NNP:[163..168] Satoh) (NNP:[169..171] S,) (NNP:[172..177] Daigo)
        (NNP:[178..179] Y) (,:[179..180] ,) (NNP:[181..189] Furukawa)
        (NNP:[190..191] Y) (VBD:[191..192] ,) (NNP:[193..197] Kato)
        (NNP:[198..199] T) (,:[199..200] ,) (NNP:[201..205] Miwa)
        (NNP:[206..207] N) (VBD:[207..208] ,) (NNP:[209..218] Nishiwaki)
        (NNP:[219..220] T) (VBD:[220..221] ,) (NNP:[222..229] Kawasoe)
        (NNP:[230..231] T) (,:[231..232] ,) (NNP:[233..241] Ishiguro)
        (NNP:[243..244] H) (,:[244..245] ,) (NNP:[246..252] Fujita)
        (VBD:[253..255] M,) (NNP:[256..262] Tokino) (NNP:[263..264] T)
        (,:[264..265] ,) (NNP:[266..272] Sasaki) (NNP:[273..274] Y)
        (,:[274..275] ,) (NNP:[276..282] Imaoka) (NNP:[283..285] S,)
        (NNP:[286..292] Murata) (VBD:[293..295] M,) (NNP:[296..303] Shimano)
        (NNP:[304..305] T) (,:[305..306] ,) (NNP:[307..314] Yamaoka)
        (NNP:[315..316] Y) (,:[316..317] ,) (NNP:[319..327] Nakamura)
        (NNP:[328..330] Y.)))

;section 3 Span:334..458
;Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical 
;Science, The University of Tokyo, Tokyo, Japan.
(SEC
  (FRAG (NN:[334..344] Laboratory) (IN:[345..347] of) (NNP:[348..357] Molecular)
        (NNP:[358..366] Medicine) (,:[366..367] ,) (NNP:[368..373] Human)
        (NNP:[374..380] Genome) (NNP:[381..387] Center) (,:[387..388] ,)
        (NNP:[389..398] Institute) (IN:[399..401] of) (NNP:[402..409] Medical)
        (NNP:[411..418] Science) (,:[418..419] ,) (DT:[420..423] The)
        (NNP:[424..434] University) (IN:[435..437] of) (NNP:[438..443] Tokyo)
        (,:[443..444] ,) (NNP:[445..450] Tokyo) (,:[450..451] ,)
        (NNP:[452..457] Japan) (.:[457..458] .)))

;sentence 4 Span:462..535
;The Wnt signaling pathway is essential for development and organogenesis.
;[466..469]:gene-rna:"Wnt"
(SENT
  (S
    (NP-SBJ (DT:[462..465] The) (NN:[466..469] Wnt) (NN:[470..479] signaling)
            (NN:[480..487] pathway))
    (VP (VBZ:[488..490] is)
      (ADJP-PRD (JJ:[491..500] essential)
        (PP (IN:[501..504] for)
          (NP (NN:[505..516] development) (CC:[517..520] and)
              (NN:[521..534] organogenesis)))))
    (.:[534..535] .)))

;sentence 5 Span:536..736
;Wnt  signaling stabilizes beta-catenin, which accumulates in the cytoplasm,
;binds to  1-cell factor (TCF; also known as lymphocyte enhancer-binding
;factor, LEF) and  then upregulates downstream genes.
;[536..539]:gene-rna:"Wnt"
;[562..574]:gene-protein:"beta-catenin"
;[637..640]:gene-protein:"TCF"
;[656..690]:gene-protein:"lymphocyte enhancer-binding factor"
;[692..695]:gene-protein:"LEF"
(SENT
  (S
    (NP-SBJ (NN:[536..539] Wnt) (NN:[541..550] signaling))
    (VP (VBZ:[551..561] stabilizes)
      (NP
        (NP (NN:[562..574] beta-catenin))
        (,:[574..575] ,)
        (SBAR
          (WHNP-1 (WDT:[576..581] which))
          (S
            (NP-SBJ-1 (-NONE-:[581..581] *T*))
            (VP
              (VP (VBZ:[582..593] accumulates)
                (PP-LOC (IN:[594..596] in)
                  (NP (DT:[597..600] the) (NN:[601..610] cytoplasm))))
              (,:[610..611] ,)
              (VP (VBZ:[612..617] binds)
                (PP (TO:[618..620] to)
                  (NP (NN:[622..628] 1-cell) (NN:[629..635] factor)
                    (PRN (-LRB-:[636..637] -LRB-)
                      (NP
                        (NP (NN:[637..640] TCF))
                        (::[640..641] ;)
                        (VP
                          (ADVP (RB:[642..646] also))
                          (VBN:[647..652] known)
                          (NP (-NONE-:[652..652] *))
                          (PP (IN:[653..655] as)
                            (NP
                              (NP (NN:[656..666] lymphocyte)
                                (NML (NN:[667..675] enhancer)
                                     (HYPH:[675..676] -)
                                     (VBG:[676..683] binding))
                                (NN:[684..690] factor))
                              (,:[690..691] ,)
                              (NP (NN:[692..695] LEF))))))
                      (-RRB-:[695..696] -RRB-)))))
              (CONJP (CC:[697..700] and) (RB:[702..706] then))
              (VP (VBZ:[707..718] upregulates)
                (NP (JJ:[719..729] downstream) (NNS:[730..735] genes))))))))
    (.:[735..736] .)))

;sentence 6 Span:737..918
;Mutations in CTNNB1 (encoding beta-catenin)  or APC (adenomatous polyposis
;coli) have been reported in human neoplasms  including colon cancers and
;hepatocellular carcinomas (HCCs).
;[750..756]:gene-rna:"CTNNB1"
;[767..779]:gene-protein:"beta-catenin"
;[785..788]:gene-rna:"APC"
;[790..816]:gene-rna:"adenomatous polyposis coli"
;[846..855]:malignancy:"neoplasms"
;[867..880]:malignancy:"colon cancers"
;[885..910]:malignancy:"hepatocellular carcinomas"
;[912..916]:malignancy:"HCCs"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[737..746] Mutations))
      (PP (IN:[747..749] in)
        (NP
          (NP (NN:[750..756] CTNNB1)
            (PRN (-LRB-:[757..758] -LRB-)
              (VP (VBG:[758..766] encoding)
                (NP (NN:[767..779] beta-catenin)))
              (-RRB-:[779..780] -RRB-)))
          (CC:[782..784] or)
          (NP
            (NP (NN:[785..788] APC))
            (NP (-LRB-:[789..790] -LRB-)
               (JJ:[790..801] adenomatous) (NN:[802..811] polyposis)
               (NN:[812..816] coli)
              (-RRB-:[816..817] -RRB-))))))
    (VP (VBP:[818..822] have)
      (VP (VBN:[823..827] been)
        (VP (VBN:[828..836] reported)
          (NP-1 (-NONE-:[836..836] *))
          (PP (IN:[837..839] in)
            (NP
              (NP (JJ:[840..845] human) (NNS:[846..855] neoplasms))
              (PP (VBG:[857..866] including)
                (NP
                  (NP (NN:[867..872] colon) (NNS:[873..880] cancers))
                  (CC:[881..884] and)
                  (NP
                    (NP (JJ:[885..899] hepatocellular)
                        (NNS:[900..910] carcinomas))
                    (NP (-LRB-:[911..912] -LRB-) (NNS:[912..916] HCCs)
                        (-RRB-:[916..917] -RRB-))))))))))
    (.:[917..918] .)))

;sentence 7 Span:919..1130
;Because HCC5 tend  to show accumulation of beta-catenin more often than
;mutations in CTNNB1, we  looked for mutations in AXIN1, encoding a key factor
;for Wnt signaling, in 6 HCC  cell lines and 100 primary HCC5.
;[927..931]:malignancy:"HCC5"
;[962..974]:gene-protein:"beta-catenin"
;[1004..1010]:gene-rna:"CTNNB1"
;[1040..1045]:gene-rna:"AXIN1"
;[1073..1076]:gene-rna:"Wnt"
;[1093..1108]:malignancy:"HCC  cell lines"
;[1117..1129]:malignancy:"primary HCC5"
(SENT
  (S
    (SBAR-PRP (IN:[919..926] Because)
      (S
        (NP-SBJ (NN:[927..931] HCC5))
        (VP (VBP:[932..936] tend)
          (S
            (NP-SBJ (-NONE-:[936..936] *))
            (VP (TO:[938..940] to)
              (VP (VB:[941..945] show)
                (NP
                  (NP (NN:[946..958] accumulation))
                  (PP (IN:[959..961] of)
                    (NP (NN:[962..974] beta-catenin))))
                (ADVP-TMP
                  (ADVP (RBR:[975..979] more) (RB:[980..985] often))
                  (PP (IN:[986..990] than)
                    (NP
                      (NP (NNS:[991..1000] mutations))
                      (PP (IN:[1001..1003] in)
                        (NP (NN:[1004..1010] CTNNB1))))))))))))
    (,:[1010..1011] ,)
    (NP-SBJ (PRP:[1012..1014] we))
    (VP (VBD:[1016..1022] looked)
      (PP-CLR (IN:[1023..1026] for)
        (NP (NNS:[1027..1036] mutations)))
      (PP-LOC (IN:[1037..1039] in)
        (NP
          (NP (NN:[1040..1045] AXIN1))
          (,:[1045..1046] ,)
          (VP (VBG:[1047..1055] encoding)
            (NP (DT:[1056..1057] a) (JJ:[1058..1061] key)
                (NN:[1062..1068] factor))
            (PP (IN:[1069..1072] for)
              (NP (NN:[1073..1076] Wnt) (NN:[1077..1086] signaling))))))
      (,:[1086..1087] ,)
      (PP (IN:[1088..1090] in)
        (NP
          (NP (CD:[1091..1092] 6)
             (NN:[1093..1096] HCC) (NN:[1098..1102] cell)
             (NNS:[1103..1108] lines))
          (CC:[1109..1112] and)
          (NP (CD:[1113..1116] 100)
             (JJ:[1117..1124] primary) (NN:[1125..1129] HCC5)))))
    (.:[1129..1130] .)))

;sentence 8 Span:1131..1300
;Among the 4 cell lines and 87 HCC5 in which we  did not detect CTNNB1
;mutations, we identified AXIN1 mutations in 3 cell lines  and 6 mutations in
;5 of the primary HCCs.
;[1161..1165]:malignancy:"HCC5"
;[1194..1200]:gene-rna:"CTNNB1"
;[1226..1231]:gene-rna:"AXIN1"
;[1287..1299]:malignancy:"primary HCCs"
(SENT
  (S
    (PP (IN:[1131..1136] Among)
      (NP
        (NP
          (NP (DT:[1137..1140] the) (CD:[1141..1142] 4) (NN:[1143..1147] cell)
              (NNS:[1148..1153] lines))
          (CC:[1154..1157] and)
          (NP (CD:[1158..1160] 87) (NN:[1161..1165] HCC5)))
        (SBAR
          (WHPP-1 (IN:[1166..1168] in)
            (WHNP (WDT:[1169..1174] which)))
          (S
            (NP-SBJ (PRP:[1175..1177] we))
            (VP (VBD:[1179..1182] did) (RB:[1183..1186] not)
              (VP (VB:[1187..1193] detect)
                (NP (NN:[1194..1200] CTNNB1) (NNS:[1201..1210] mutations))
                (PP-1 (-NONE-:[1210..1210] *T*))))))))
    (,:[1210..1211] ,)
    (NP-SBJ (PRP:[1212..1214] we))
    (VP (VBD:[1215..1225] identified)
      (NP
        (NP
          (NP (NN:[1226..1231] AXIN1) (NNS:[1232..1241] mutations))
          (PP (IN:[1242..1244] in)
            (NP (CD:[1245..1246] 3) (NN:[1247..1251] cell)
                (NNS:[1252..1257] lines))))
        (CC:[1259..1262] and)
        (NP
          (NP (CD:[1263..1264] 6) (NNS:[1265..1274] mutations))
          (PP (IN:[1275..1277] in)
            (NP
              (NP (CD:[1278..1279] 5))
              (PP (IN:[1280..1282] of)
                (NP (DT:[1283..1286] the)
                   (JJ:[1287..1294] primary) (NNS:[1295..1299] HCCs))))))))
    (.:[1299..1300] .)))

;sentence 9 Span:1301..1434
;In cell lines containing mutations in  either gene, we observed increased DNA
;binding of TCF associated with  beta-catenin in nuclei.
;[1390..1393]:gene-protein:"TCF"
;[1411..1423]:gene-protein:"beta-catenin"
(SENT
  (S
    (PP (IN:[1301..1303] In)
      (NP
        (NP (NN:[1304..1308] cell) (NNS:[1309..1314] lines))
        (VP (VBG:[1315..1325] containing)
          (NP (NNS:[1326..1335] mutations))
          (PP (IN:[1336..1338] in)
            (NP (DT:[1340..1346] either) (NN:[1347..1351] gene))))))
    (,:[1351..1352] ,)
    (NP-SBJ (PRP:[1353..1355] we))
    (VP (VBD:[1356..1364] observed)
      (NP
        (NP
          (NP (VBN:[1365..1374] increased) (NN:[1375..1378] DNA)
              (NN:[1379..1386] binding))
          (PP (IN:[1387..1389] of)
            (NP (NN:[1390..1393] TCF))))
        (VP (VBN:[1394..1404] associated)
          (NP (-NONE-:[1404..1404] *))
          (PP-CLR (IN:[1405..1409] with)
            (NP (NN:[1411..1423] beta-catenin)))))
      (PP-LOC (IN:[1424..1426] in)
        (NP (NNS:[1427..1433] nuclei))))
    (.:[1433..1434] .)))

;sentence 10 Span:1435..1774
;Adenovirus mediated gene transfer of wild-type AXINI  induced apoptosis in
;hepatocellular and colorectal cancer cells that had  accumulated beta-catenin
;as a consequence of either APC, CTNNB1 or AXIN1  mutation, suggesting that
;axin may be an effective therapeutic molecule for  suppressing growth of
;hepatocellular and colorectal cancers.
;[1482..1487]:gene-rna:"AXINI"
;[1510..1524]...[1540..1552]:malignancy:"hepatocellular"..."cancer cells"
;[1529..1552]:malignancy:"colorectal cancer cells"
;[1575..1587]:gene-protein:"beta-catenin"
;[1615..1618]:gene-rna:"APC"
;[1620..1626]:gene-rna:"CTNNB1"
;[1630..1635]:gene-rna:"AXIN1"
;[1663..1667]:gene-protein:"axin"
;[1736..1750]...[1766..1773]:malignancy:"hepatocellular"..."cancers"
;[1755..1773]:malignancy:"colorectal cancers"
(SENT
  (S
    (NP-SBJ
      (NP
        (ADJP (NN:[1435..1445] Adenovirus) (VBD:[1446..1454] mediated))
        (NN:[1455..1459] gene) (NN:[1460..1468] transfer))
      (PP (IN:[1469..1471] of)
        (NP
          (NML (JJ:[1472..1476] wild) (HYPH:[1476..1477] -)
               (NN:[1477..1481] type))
          (NN:[1482..1487] AXINI))))
    (VP (VBN:[1489..1496] induced)
      (NP (NN:[1497..1506] apoptosis))
      (PP-LOC (IN:[1507..1509] in)
        (NP
          (NP
            (NP (JJ:[1510..1524] hepatocellular)
              (NML-4 (-NONE-:[1524..1524] *P*)))
            (CC:[1525..1528] and)
            (NP (JJ:[1529..1539] colorectal)
              (NML-4 (NN:[1540..1546] cancer) (NNS:[1547..1552] cells))))
          (SBAR
            (WHNP-3 (WDT:[1553..1557] that))
            (S
              (NP-SBJ-3 (-NONE-:[1557..1557] *T*))
              (VP (VBD:[1558..1561] had)
                (VP (VBN:[1563..1574] accumulated)
                  (NP (NN:[1575..1587] beta-catenin))
                  (PP (IN:[1588..1590] as)
                    (NP
                      (NP (DT:[1591..1592] a) (NN:[1593..1604] consequence))
                      (PP (IN:[1605..1607] of)
                        (NP (CC:[1608..1614] either)
                          (NP (NN:[1615..1618] APC)
                            (NML-2 (-NONE-:[1618..1618] *P*)))
                          (,:[1618..1619] ,)
                          (NP (NN:[1620..1626] CTNNB1)
                            (NML-2 (-NONE-:[1626..1626] *P*)))
                          (CC:[1627..1629] or)
                          (NP (NN:[1630..1635] AXIN1)
                            (NML-2 (NN:[1637..1645] mutation)))))))))))))
      (,:[1645..1646] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1646..1646] *))
        (VP (VBG:[1647..1657] suggesting)
          (SBAR (IN:[1658..1662] that)
            (S
              (NP-SBJ (NN:[1663..1667] axin))
              (VP (MD:[1668..1671] may)
                (VP (VB:[1672..1674] be)
                  (NP-PRD
                    (NP (DT:[1675..1677] an) (JJ:[1678..1687] effective)
                        (JJ:[1688..1699] therapeutic) (NN:[1700..1708] molecule))
                    (PP (IN:[1709..1712] for)
                      (S-NOM
                        (NP-SBJ (-NONE-:[1712..1712] *))
                        (VP (VBG:[1714..1725] suppressing)
                          (NP
                            (NP (NN:[1726..1732] growth))
                            (PP (IN:[1733..1735] of)
                              (NP
                                (NP (JJ:[1736..1750] hepatocellular)
                                  (NML-1 (-NONE-:[1750..1750] *P*)))
                                (CC:[1751..1754] and)
                                (NP (JJ:[1755..1765] colorectal)
                                  (NML-1 (NNS:[1766..1773] cancers)))))))))))))))))
    (.:[1773..1774] .)))

;section 11 Span:1778..1823
;PMID: 10700176 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1778..1782] PMID) (::[1782..1783] :) (CD:[1784..1792] 10700176)
        (IN:[1793..1794] -LSB-) (NNP:[1794..1800] PubMed) (HYPH:[1801..1802] -)
        (JJ:[1803..1810] indexed) (IN:[1811..1814] for)
        (NNP:[1815..1823] MEDLINE-RSB-)))
